AC Immune (NASDAQ:ACIU) Earns “Buy” Rating from HC Wainwright

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $16.00 price objective on the stock.

AC Immune Stock Performance

Shares of NASDAQ ACIU opened at $2.29 on Friday. AC Immune has a 1 year low of $2.19 and a 1 year high of $4.98. The firm has a market cap of $226.57 million, a price-to-earnings ratio of -4.98 and a beta of 1.23. The stock’s 50-day simple moving average is $2.61 and its 200-day simple moving average is $2.98.

Hedge Funds Weigh In On AC Immune

A number of hedge funds and other institutional investors have recently bought and sold shares of ACIU. Squarepoint Ops LLC acquired a new position in shares of AC Immune during the fourth quarter worth approximately $118,000. Jane Street Group LLC bought a new position in shares of AC Immune in the fourth quarter valued at $66,000. Two Sigma Advisers LP bought a new position in shares of AC Immune in the fourth quarter valued at $36,000. Northern Trust Corp bought a new position in shares of AC Immune in the fourth quarter valued at $1,088,000. Finally, Dimensional Fund Advisors LP raised its stake in AC Immune by 130.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company’s stock valued at $355,000 after purchasing an additional 74,358 shares during the period. 51.36% of the stock is currently owned by institutional investors and hedge funds.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.